<DOC>
	<DOC>NCT00879008</DOC>
	<brief_summary>In this study data of patients with moderate or severe acute exacerbations of chronic bronchitis (AECB) were collected. There were two different cohorts which were compared (Moxifloxacin and other antibiotics) concerning effectiveness and tolerance. It was a prospective study which was accomplished in 100 ambulatory practice offices.</brief_summary>
	<brief_title>SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe Acute Exacerbations of Chronic Bronchitis (AECB)</brief_title>
	<detailed_description>The study design was slightly changed to adapt the target population. Due to these changes the study was restarted on 8th December 2009.</detailed_description>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Bronchitis, Chronic</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<criteria>Acute exacerbation of chronic bronchitis from Anthonisen type I or II FEV1 of &lt; 50 % Patient must be ensured in the statutory health insurance Further contraindications of the prescribed pharmaceutical products must be considered Patients who change from one cohort to the other</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Disease Exacerbation</keyword>
	<keyword>Acute Exacerbations of Chronic Bronchitis</keyword>
	<keyword>AECB</keyword>
	<keyword>Avelox</keyword>
	<keyword>Bronchitis</keyword>
</DOC>